Schwicker, David / Banz, Kurt
RoferonÎ-A in Chronic Viral Hepatitis
Treatment - Clinical Outcomes - Cost-Effectiveness
Year of Publication: 1994
Bern, Berlin, Frankfurt/M., New York, Paris, Wien, 1994. 115 pp.
ISBN 978-3-906752-66-2 pb. (Softcover)
Weight: 0.220 kg, 0.485 lbs
- SFR 62.00
- €* 55.30
- €** 56.90
- € 51.70
- £ 41.00
- US$ 67.95
» Currency of invoice
* includes VAT – valid for Germany and EU customers without VAT Reg No
** includes VAT - only valid for Austria
Chronic liver infection due to viral hepatitis B and C is a major public health problem. Worldwide, an estimated 750 million people are carriers of these two viruses. Alpha-interferons, such as RoferonÎ-A, are currently the therapy of choice in chronic viral hepatitis B and C. They are effective in preventing disease progression and life-threatening sequelae: liver cirrhosis, ascites, hepatic encephalopathy, and variceal hemorrhage and/or hepatocellular carcinoma. On the other hand, discussion has been raised on the potentially enormous cost impact of these genetically engineered drugs in the treatment of an already costly disease.
This study identifies and evaluates the long-term clinical and economic effects of RoferonÎ-A treatment in chronic viral hepatitis B and C over a time period of 10 to 20 years. Clinical and epidemiological data, as well as the detailed health care resource use and cost assessment, reflect the clinical and economic reality in Germany in 1993. A Markov model is used to predict the long-term clinical benefits of RoferonÎ-A therapy in terms of reduced morbidity and mortality. Based on this, direct costs, savings, and cost-effectiveness are analysed, including: RoferonÎ-A therapy initiation and follow-up, physician services, laboratory services, medicotechnical services, drug therapy, hospitalization as well as surgical interventions (liver transplantations).
About the author(s)/editor(s)
The authors: David Schwicker was born in Cologne, Germany, in 1963. He holds a degree in economics from the University of Basle. After working in international trade and banking in Europe and Asia, he joined HealthEcon in 1990. Since then he has been working as business consultant and project manager specializing in health-economics research studies.
Kurt Banz, born 1954 in Grenchen, Switzerland, studied biology at the University of Berne, where he graduated in 1983. His interests in pharmaceuticals led him to work as a scientific clinical researcher with F. Hoffmann-La Roche Ltd. from 1984 to 1988. He joined HealthEcon in 1988 as health care consultant and manager of health- and pharmaco-economic research projects.
Gesundheit und Ökonomie. Band 6
Herausgegeber: HealthEcon AG, Basel